Corbus Pharmaceuticals

Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020

Ziad2022-11-25T14:02:05-05:00 Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the presentation of three abstracts at the American College of Rheumatology (“ACR”) Convergence 2020 being held online, November 5–9, 2020. Read more >>

Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint

Ziad2022-11-25T14:02:27-05:00 Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced topline results from its 28-week Phase 2b study of lenabasum in patients with cystic fibrosis (CF). The study enrolled patients in the U.S., Canada and Europe at high risk for recurrent pulmonary exacerbations (PEx). Subjects received lenabasum or placebo added to their background treatments for CF. Read more >>

Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Ziad2022-11-25T14:02:27-05:00 Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced topline results from the 52-week Phase 3 RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic sclerosis (SSc). Read more >>

Cannabis and Science

Ziad2022-11-25T14:02:28-05:00 In the 1980s and 1990s, researchers identified cannabinoid receptors in humans (CB1 for THC and CB2 for CBD). What they were uncovering was the human body’s own endocannabinoid system (ECS). “It’s a system as ancient as our immune system and our central nervous system. They co-evolved and our endocannabinoid system acts as a bridge between the two,” says Yuval Cohen, CEO and Director of Corbus Pharmaceuticals. Read more >>

Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates

Ziad2022-11-25T14:02:28-05:00 Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today reported financial results for the second quarter of 2020. The Company also provided clinical and corporate updates. Read more >>

Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Ziad2022-11-25T14:02:28-05:00 Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the completion of subject enrollment in DETERMINE, a Phase 3 study assessing the efficacy and safety of lenabasum for the treatment of dermatomyositis. Read more >>

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences

Ziad2022-11-25T14:02:28-05:00 Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at two upcoming conferences. Read more >>

Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors

Ziad2022-11-25T14:02:28-05:00 Corbus Pharmaceuticals, a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (ECS), today announced the appointment of George Golumbeski, Ph.D., to its Board of Directors. Read more >>

Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

Ziad2022-11-25T14:02:28-05:00 Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that the last subject completed their final visit in the Company’s Phase 2b JBT101-CF-002 trial of lenabasum for the treatment of cystic fibrosis. Read more >>

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress

Ziad2022-11-25T14:02:38-05:00 Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the publication of two abstracts at the European League Against Rheumatism (EULAR) 2020 E-Congress that will be taking place June 3-6, 2020. Read more >>